Greenstreet Yvonne 4

Accession 0001735276-26-000014

CIK 0001178670other

View on SEC.gov Company Profile

Filed

Jan 13, 7:00 PM ET

Accepted

Jan 14, 4:23 PM ET

Size

43.9 KB

Accession

0001735276-26-000014

Insider Transaction Report

Form 4

Period: 2026-01-11

ALNYLAM PHARMACEUTICALS, INC.ALNY

Greenstreet Yvonne

DirectorChief Executive Officer

Transactions

Award
Common Stock
[F1]
2026-01-11+19,003→ 87,988 total
Sale
Common Stock
[F2][F3]
2026-01-12$353.95/sh−247$87,426→ 87,741 total
Sale
Common Stock
[F2][F4]
2026-01-12$355.16/sh−269$95,538→ 87,472 total
Sale
Common Stock
[F2][F5]
2026-01-12$356.09/sh−263$93,652→ 87,209 total
Sale
Common Stock
[F2][F6]
2026-01-12$357.17/sh−607$216,802→ 86,602 total
Sale
Common Stock
[F2][F7]
2026-01-12$358.18/sh−778$278,664→ 85,824 total
Sale
Common Stock
[F2][F8]
2026-01-12$359.14/sh−537$192,858→ 85,287 total
Sale
Common Stock
[F2][F9]
2026-01-12$360.22/sh−980$353,016→ 84,307 total
Sale
Common Stock
[F2][F10]
2026-01-12$361.45/sh−624$225,545→ 83,683 total
Sale
Common Stock
[F2][F11]
2026-01-12$362.38/sh−464$168,144→ 83,219 total
Sale
Common Stock
[F2][F12]
2026-01-12$363.55/sh−301$109,429→ 82,918 total
Sale
Common Stock
[F2][F13]
2026-01-12$364.83/sh−1,259$459,321→ 81,659 total
Sale
Common Stock
[F2][F14]
2026-01-12$365.56/sh−1,395$509,956→ 80,264 total
Sale
Common Stock
[F2][F15]
2026-01-12$366.41/sh−316$115,786→ 79,948 total
Sale
Common Stock
[F2][F16]
2026-01-12$367.40/sh−261$95,891→ 79,687 total
Sale
Common Stock
[F2][F17]
2026-01-12$368.62/sh−584$215,274→ 79,103 total
Sale
Common Stock
[F2][F18]
2026-01-12$369.48/sh−253$93,478→ 78,850 total
Sale
Common Stock
[F2][F19]
2026-01-12$370.87/sh−118$43,763→ 78,732 total
Sale
Common Stock
[F2][F20]
2026-01-12$372.46/sh−21$7,822→ 78,711 total
Sale
Common Stock
[F2][F21]
2026-01-12$374.44/sh−88$32,951→ 78,623 total
Sale
Common Stock
[F2]
2026-01-12$375.65/sh−118$44,327→ 78,505 total
Sale
Common Stock
[F2]
2026-01-12$377.82/sh−94$35,515→ 78,411 total

Holdings

Common Stock
[F22]
(indirect: by Managed Account)
407

Footnotes (22)

[F1]On March 1, 2024, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of forty (40) percent of the shares subject to the PSU based on the issuer publicly reporting $2.5 billion in annual net product revenue in accordance with GAAP, as determined by the People, Culture and Compensation Committee of the Issuer Board of Directors on January 11, 2026.
[F10]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $360.90 to $361.89. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F11]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $361.93 to $362.92. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F12]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $362.99 to $363.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F13]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $364.00 to $365.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F14]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $365.01 to $366.01. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F15]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $366.03 to $366.96. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F16]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $367.04 to $368.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F17]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $368.09 to $369.08. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F18]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $369.13 to $369.93. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F19]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $370.43 to $371.23. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F2]Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations.
[F20]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $372.35 to $372.50. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F21]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $374.08 to $374.89. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F22]Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.
[F3]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $353.53 to $354.41. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F4]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $354.54 to $355.53. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F5]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $356.62 to $356.61. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F6]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $356.63 to $357.63. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F7]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $357.68 to $358.68. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F8]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $358.69 to $359.66. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F9]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $359.79 to $360.79. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Signature

By: Brett Budzinski, Attorney-in-Fact For: Yvonne Greenstreet|2026-01-14

Documents

1 file

4
edgardoc.xmlPrimary
PRIMARY DOCUMENT

Issuer

ALNYLAM PHARMACEUTICALS, INC.

CIK 0001178670

→

Entity typeother

Related Parties

filerCIK 0001446125

Filing Metadata

Form type: 4
Filed: Jan 13, 7:00 PM ET
Accepted: Jan 14, 4:23 PM ET
Size: 43.9 KB

View on SEC.gov